PTEN negatively regulates mTORC2 formation and signaling in grade IV glioma via Rictor hyperphosphorylation at Thr1135 and direct the mode of action of an mTORC1/2 inhibitor

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

(2016) Linda S. Steelman et al.   Aging-US

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs

(2015)   Oncotarget

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

(2015) William H. Chappell et al.   Oncotarget

Improved chemosensitivity in cervical cancer to cisplatin: Synergistic activity of mahanine through STAT3 inhibition

(2014) Ranjita Das et al.   CANCER LETTERS

Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcinoma

(2013) Ranjita Das et al.   APOPTOSIS

Mahanine, A DNA Minor Groove Binding Agent Exerts Cellular Cytotoxicity with Involvement of C-7-OH and −NH Functional Groups

(2013) Suman K. Samanta et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cellular response to chirality and amplified chirality

(2013) Sarita Roy et al.   Journal of Materials Chemistry B

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Temporal Changes in PTEN and mTORC2 Regulation of Hematopoietic Stem Cell Self-Renewal and Leukemia Suppression

(2012) Jeffrey A. Magee et al.   Cell Stem Cell

Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinomain vitroandin vivo

(2012) Sayantani Sarkar et al.   INTERNATIONAL JOURNAL OF CANCER

Endogenous viruses: insights into viral evolution and impact on host biology

(2012) Cédric Feschotte et al.   NATURE REVIEWS GENETICS

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

(2011) Seth A. Wander et al.   JOURNAL OF CLINICAL INVESTIGATION

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives

(2011) Marc Dufour et al.   Cancers

Rictor Phosphorylation on the Thr-1135 Site Does Not Require Mammalian Target of Rapamycin Complex 2

(2010) D. Boulbes et al.   MOLECULAR CANCER RESEARCH

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

Apoptotic effects of mahanine on human leukemic cells are mediated through crosstalk between Apo-1/Fas signaling and the Bid protein and via mitochondrial pathways

(2009) Kaushik Bhattacharya et al.   BIOCHEMICAL PHARMACOLOGY

mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice

(2009) David A. Guertin et al.   CANCER CELL

Genetic alterations and signaling pathways in the evolution of gliomas

(2009) Hiroko Ohgaki et al.   CANCER SCIENCE

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

Insulin resistance due to lipid-induced signaling defects could be prevented by mahanine

(2009) Anindita Biswas et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1

(2009) C. C. Dibble et al.   MOLECULAR AND CELLULAR BIOLOGY

mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling

(2009) L.-A. Julien et al.   MOLECULAR AND CELLULAR BIOLOGY

Rictor is a novel target of p70 S6 kinase-1

(2009) C Treins et al.   ONCOGENE

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling